Synthesis and antiproliferative activity of C-3 functionalized isobenzofuran-1(3H)-ones

Article abstract of DOI:10.3390/molecules18021881

A series of thirteen C-3 functionalized isobenzofuran-1(3H)-ones (phtalides) was synthesized via condensation, aromatization, and acetylation reactions. NMR (one and two dimensional experiments), IR, and mass spectrometry analysis allowed confirmation of

Full text of DOI:10.3390/molecules18021881

Molecules 2013, 18, 1881-1896; doi:10.3390/molecules18021881
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis and Antiproliferative Activity of C-3 Functionalized
Isobenzofuran-1(3H)-ones
Róbson Ricardo Teixeira 1,*, Gustavo Costa Bressan 2,*, Wagner Luiz Pereira 1,
Joana Gasperazzo Ferreira 2, Fabrício Marques de Oliveira 1 and Deborah Campos Thomaz 1
1
Departamento de Química, Universidade Federal de Viçosa, Av. P.H. Rolfs, S/N, CEP 36.570-000,
Viçosa, MG, Brazil
2
Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa,
Av. P.H. Rolfs, S/N, CEP 36.570-000, Viçosa, MG, Brazil
* Authors to whom correspondence should be addressed: E-Mails: robsonr.teixeira@ufv.br (R.R.T.);
gustavo.bressan@ufv.br (G.C.B.); Tel.: +55-31-3899-3209 (R.R.T.); Fax: +55-31-3899-2370 (R.R.T.);
Tel.: +55-31-3899-3714 (G.C.B.); Fax: +55-31-3899-2373 (G.C.B.).
Received: 25 October 2012; in revised form: 20 December 2012 / Accepted: 24 December 2012 /
Published: 1 February 2013
Abstract: A series of thirteen C-3 functionalized isobenzofuran-1(3H)-ones (phtalides)
was synthesized via condensation, aromatization, and acetylation reactions. NMR (one and
two dimensional experiments), IR, and mass spectrometry analysis allowed confirmation of
the identity of the synthesized compounds. The substances were submitted to in vitro
bioassays against U937 (lymphoma) and K562 (myeloid leukemia) cancer cell lines using
the MTT cytotoxicity assay. Some derivatives inhibited 90% of cell viability at 100 µM.
Also, two phtalides presented biological activity superior than that of etoposide (VP16), a
commercial drug used as a positive control in the assays. In silico drug properties of the
evaluated compounds were calculated and the results are discussed.
Keywords: isobenzofuran-1(3H)-one; phtalides; antiproliferative activity
1. Introduction
Several compounds possessing a -lactone moiety fused to an aromatic ring, known as isobenzofuran-
1(3H)-ones (phtalides), exhibit many biological activities: antioxidant, presented by compounds 1 and
2 [1]; antifungal, displayed by isopestacin (3) [2]; anti-platelet observed with the brominated derivative

Molecules 2013, 18
1882
4 [3]; and anticonvulsant activity related to compound 5 [4] (Figure 1). The phytotoxic compound 6 [5],
the photosynthetic inhibitor 7 [6] and the cytotoxic substances 8 and 9 are other examples of bioactive
phtalides. As can be seen in Figure 1, various phtalides are functionalized at C-3 position (see structure
1 for numbering).
Figure 1. Structures of isobenzofuran-1(3H)-ones 1–9.
CH3
OH
HO
CH3
O
O
O
7
HO
6
8
HO
HO
1
2
O
O
O
5
H3CO
9
HO
4
OH
3
OH
OH
(1)
(2)
(3)
OH
O
O
O
O
O
Br
O
HO
OH
HO
(4)
5
( )
COOH
(6)
OMe
OMe
O
O
O
O
O
O
O
H3C
C13H27
C13H27
OCH3
HO
O
7
( )
(8)
(9)
The isobenzofuranones 8 and 9 were prepared from anarchadic acids, the major natural phenolic
lipid in cashew (Anacardium occidentale) nut-shells [7]. Cytotoxicity screening of compounds 8 and 9
against different human cancer cell lines (HL-60 leukemia, SF295 glioblastoma and MDA-MB435
melanoma) by the MTT assay showed that they are active. Compound 8 exhibited low activity against
HL-60 (IC50 21.00 µg/mL) and SF295 (IC50 > 25 µg/mL) cells, and moderate activity against
MDA-MB435 cells (IC50 12.17 µg/mL), while compound 9 exhibited a significant cytotoxic effect
against HL-60 cells (IC50 3.24 µg/mL), and moderate activity on SF295 (IC50 10.09 µg/mL) and
MDA-MB435 (IC50 8.70 µg/mL). The two compounds exhibited weak to moderate activities against
PBMC cells (8, IC50 > 25 µg/mL; 9, IC50 > 14.51 µg/mL).
A natural extension of this investigation would be the synthesis and cytotoxic screening of
isobenzofuranones structurally similar to compounds 8 and 9 but containing alicyclic and aromatic
functionalities attached to C-3 position. Considering the aforementioned cytotoxic effects of 8 and 9
and our interest in the development of bioactive compounds [8–11], we detail in this paper the
synthesis and evaluation of the antiproliferative activity of a series of alicyclic and aromatic C-3

Molecules 2013, 18
1883
functionalized isobenzofuranones. In silico drug properties of the evaluated compounds were
determined and the results are also discussed.
2. Results and Discussion
2.1. Preparation of Isobenzofuran-1(3H)-ones
The synthetic route used to prepare compounds 11–22, functionalized at C-3 position of the
isobenzofuranone core, is outlined in Scheme 1.
Scheme 1. Synthetic route involved in the preparation of compounds 11–22.
O
7
1
8
6
2
O
5
3
9
4
1'
OH
5'
2'
O
21
(
)
3'
4'
O
O
(i)
O
O
O
O
O
O
O
O
7
4
7
4
1
1
8
9
8
9
6
5
O
6
5
2
2
O
O
O
O
3
3
R
(iii)
OH
2'
OH
OAc
O
1'
1'
OH
6'
5'
6'
(v)
(iv)
2'
3'
(ii)
O
HO
AcO
O
3'
OH
)
10
4'
(
5'
4'
R
R
R
O
(20)
(11) R = H
12
(14) R = H
) R = CH3
(17) R = H
18
O
15
(
) R = CH3
(
(
) R = CH3
(i)
(13) R = i-Pr
(16) R = i-Pr
(19) R = i-Pr
O
O
O
O
(22)
Reagents and Conditions: (i) DBU, CHCl3, reflux; (ii) DBU, CHCl3, r.t.; (iii) DBU, CH3CN, reflux;
(iv) Hg(OAc)2, NaOAc, CH3COOH, reflux; (v) DMAP, Ac2O, CHCl3, r.t.
DBU-promoted condensation of commercially available phthalaldehydic acid (10) and different
1,3-dicarbonyl compounds afforded derivatives 11–13 and 20–22 in yields varying from 53 to
95% [12,13]. Phenolic compounds 14–16 were prepared via Hg(OAc)2 mediated aromatization [14].
Treatment of substances 14–16 with Ac2O/DMAP resulted in the formation of acetylated derivatives
17–19. The compounds were fully characterized by IR, NMR, and MS analysis. High resolution mass
spectrometry confirmed the molecular formula of the compounds. A combination of two dimensional
NMR analyses (HSQC and HMBC) allowed complete hydrogen and carbon assignments. Taking
compound 14 into consideration, some of the major long-range correlations (J2 and J3) observed in the
HMBC contour plot are depicted in Scheme 2.

Molecules 2013, 18
Scheme 2. Some long range correlations found in the HMBC contour plot of compound 14.
1884
H
O
H
H
6
8
1
O
3
4
H
OH
H
1´
HO
3´
H
5´
H
H
2.2. Evaluation of Antiproliferative Activity
Isobenzofuran-1(3H)-ones 10–22 were biologically evaluated against U937 (lymphoma) and K562
(myeloid leukemia) cell lines in comparison to DMSO (1%) and etoposide (VP16), used as negative
and positive controls, respectively. After 48 h of treatment, compounds 16–18 were the most effective
in decreasing the viability of both the cell lines tested (Tables 1 and 2). Compound 19 also inhibited
proliferation, though only against K562 cells. Although the IC50 values obtained for compounds 16–18
suggest a moderate effect on U937 cells, a strong inhibitory activity was observed for compounds 16
and 18 against K562 cells (IC50 2.79 and 1.71 µM, respectively; Table 3 and Figure 2). More importantly,
these inhibitory activities were even higher than those observed for etoposide (VP16) (IC50 7.06 µM
for K562), an anticancer drug used in several chemotherapy regimes, including against leukemia.
Table 1. Inhibitory effects (%) a of compounds 10–22 on K562 cell viability (mean ± SD; n = 4).
Comp.
10
1 µM
50 µM
100 µM
44.16 ± 3.59 41.71 ± 1.01 26.71 ± 3.91
49.69 ± 0.68 45.85 ± 3.07 36.18 ± 1.00
31.42 ± 1.18 38.38 ± 3.04 38.54 ± 4.24
32.87 ± 3.20 23.93 ± 3.04 31.64 ± 2.93
37.71 ± 2.20 49.33 ± 4.70 56.82 ± 1.36
40.59 ± 2.47 44.32 ± 1.08 43.64 ± 3.85
20.33 ± 1.13 65.61 ± 2.42 77.73 ± 2.01
26.77 ± 0.99 56.10 ± 3.58 63.70 ± 0.21
37.88 ± 3.86 69.63 ± 0.92 80.05 ± 0.28
12.48 ± 3.57 54.56 ± 2.97 71.76 ± 3.73
39.87 ± 4.43 43.86 ± 1.92 49.38 ± 2.50
20.64 ± 1.91 18.60 ± 2.65 21.84 ± 3.39
11
12
13
14
15
16
17
18
19
20
21
22
46.11 ± 4.1
45.9 ± 3.39
37.61 ± 0.38
a
inhibition (%) after 48 h of continuous treatment (n = 4), normalized against K562 cells treated with 1%
DMSO (n = 4).

Molecules 2013, 18
1885
Table 2. Inhibitory effects (%) a of compounds 10–22 on U937 cell viability (mean ± SD; n = 4).
Comp.
10
1 µM
50 µM
100 µM
28.00 ± 2.75 30.73 ± 2.12 28.81 ± 2.05
32.34 ± 1.93 28.58 ± 1.62 29.43 ± 2.76
20.38 ± 3.04 27.01 ± 3.68 24.72 ± 1.48
26.75 ± 2.12 45.31 ± 1.91 39.10 ± 0.92
25.57 ± 2.50 31.10 ± 3.53 29.86 ± 1.70
35.03 ± 2.05 27.03 ± 0.61 22.37 ± 1.13
11.64 ± 0.28 58.86 ± 2.62 90.82 ± 0.43
33.87 ± 0.92 61.33 ± 1.98 83.91 ± 0.92
36.63 ± 1.98 67.68 ± 1.77 90.78 ± 0.21
23.14 ± 3.19 25.46 ± 3.13 23.12 ± 3.43
24.33 ± 0.47 30.98 ± 1.04 34.14 ± 0.49
5.72 ± 1.27 21.17 ± 1.48 29.29 ± 2.02
27.63 ± 0.92 31.85 ± 0.99 33.58 ± 2.71
11
12
13
14
15
16
17
18
19
20
21
22
a
inhibition (%) after 48 h of continuous treatment (n = 4), normalized against U937 cells treated with 1%
DMSO (n = 4).
Table 3. IC50 values (µM) a obtained when K562 and U937 cells were treated with compounds
16–18 and positive control etoposide (VP16).
Cell line Comp. 16 Compound 17 Compound 18 Etoposide (VP16)
K562
U937
2.79
66.81
71.39
1.71
7.06
0.35
62.97
46.63
a IC50: compound concentration required to inhibit 50% of cell viability, determined after 48 h of continuous
treatment (n = 4).
Figure 2. Dose-response profiles of compounds 16–18 and positive control VP16 on
viability of K562 (A) and U937 (B) cells. K562 and U937 cell lines were treated for 48 h
with increasing amounts of the indicated substances. All the assays were performed in
quadruplicates and the results were normalized considering the cultures treated with the
vehicle alone (1% DMSO).
150
100
50
A
16
17
18
VP16
0
-8
-7
-6
-5
-4
-3
Log compounds (Mol/L)
-50

Molecules 2013, 18
1886
Figure 2. Cont.
150
100
50
B
16
17
18
VP16
0
-8
-7
-6
-5
-4
-3
Log compounds (Mol/L)
-50
2.3. Structure-Activity Relationship and in Silico Calculations of Drug-Like Properties
Considering the therapeutic potential of the isobenzofuranone derivatives described so far, a
computational study was carried out to predict the physical chemical properties of compounds 10–22.
These parameters influence pharmacokinetic properties, such as absorption, distribution, metabolism,
and excretion (ADME). A screening was conducted to evaluate whether the substances can fulfill the
characteristics of candidate drugs, based on Lipinski’s Rule of Five [15] and other related criteria
added later by Veber and co-workers [16]. These characteristics theoretically determine if a compound
presents absorptivity on and permeability across membranes, properties that would likely make it an
orally active drug in humans.
Molecular attributes analyzed were n-octanol/water partition coefficient (LogP ≤ 5), the amount of
hydrogen bond donors (HBD ≤ 5), the amount of hydrogen bond acceptor (HBA ≤ 10), the molecular
weight of the drugs (MW ≤ 500), number of rotatable bonds (nRotb < 10) and polar surface area
(PSA < 140 Å2). Values in parentheses represent the ideal values according to Lipinski [15] and
Veber [16]. Physicochemical parameters were calculated by using Osiris Property Explorer [17] and
Molinspiration [18], good free computational tools which help to predict pharmacokinetic properties of
candidate drugs used by several research groups [19–22].
The Osiris Property Explorer allows evaluation of chemical and physicochemical data that influence
the pharmacokinetic properties of a drug. The Osiris calculations for toxicity and drug-likeness follow
a fragment-based approach. The software can calculate lipophilicity, inferred from LogP value,
solubility in water, expressed as LogS, molecular weight, drug-likeness indices and drug scores. Low
hydrophilicity, and therefore high LogP values, may cause poor absorption or permeation. Also, Osiris
software calculates various attributes of the drugs, such as toxicity risks (mutagenic, tumorigenic,
irritant and reproductive effects), drug likeness, and drug score [23,24]. Calculation of LogP and
molecular weight, as well as total polar surface area (TPSA), number of rotatable bonds (nRotB),
number of hydrogen bond donor (HBD), number of hydrogen bond acceptor (HBA) and bioactivity
scores [25] can also be determined in the Molinspiration package. Tables 4 and 5 show the results of
the calculations based on these computational packages.

Molecules 2013, 18
1887
Table 4. Predicted drug-likeness properties and toxicity risks of compounds 10–22 and
epotoside calculated by Osiris package.
Bioavailability and Drug Score
Toxicity risks a
Lipinski’s
violations
Comp.
Drug-
likeness
−4.65
−6.63
−3.61
−4.20
−4.26
−5.25
−6.33
−6.34
−7.52
−8.59
−3.58
−3.95
−4.12
−0.28
Drug-
Score
0.49
0.46
0.46
0.43
0.46
0.44
0.39
0.40
0.38
0.32
0.45
0.48
0.41
0.39
cLogP LogS MW HBD HBA
M
T I R
10
11
12
13
14
15
16
17
18
19
20
21
22
0.64 −1.68 150.0
1.78 −2.71 244.0
1.98 −2.87 258.0
2.78 −3.30 286.0
2.55 −2.66 242.0
2.87 −3.01 256.0
3.65 −3.53 284.0
3.10 −3.54 326.0
3.41 −3.88 340.0
4.19 −4.41 368.0
2.25 −3.05 272.0
1.29 −2.42 230.0
2.32 −4.04 278.0
1
1
1
1
2
2
2
2
2
2
1
0
0
3
3
4
0
0
0
0
0
0
0
0
0
0
0
0
0
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
4
4
4
4
6
6
6
4
4
4
Etoposide 0.53 −3.95 588.0
13
cLogP, calculated lipophilicity; LogS, logarithm of aqueous solubility measured in mol.L−1; MW, molecular
weight; HBD, number of hydrogen bond donor; HBA, number of hydrogen bond acceptor; M, mutagenic
a
effect; T, tumorigenic effect; I, irritating effect; R, reproductive effect. Ranked according to: (−), no bad
effect; (±), medium bad effect; (+), bad effect.
Table 5. Drug-likeness calculations of compounds 10–22 by using Molinspiration package.
Molinspiration calculations
Calculations of Bioactivity Scores a
GPCRL ICM KI NRL PI
−0.04 −1.12 −0.62 −0.95
Comp.
cLogP TPSA b NONI c Volume nRotB
EI
0.14
10
11
12
13
14
15
16
17
18
19
20
21
22
0.895 46.533
1.741 63.604
1.982 63.604
3.483 63.604
3.016 66.761
3.416 66.761
4.48 66.761
2.183 100.903
2.584 100.903
3.647 100.903
2.394 63.604
0.652 60.447
2.394 60.447
1
1
1
1
2
2
2
2
2
2
1
0
0
3
126.015
211.979
228.566
261.955
205.442
222.003
255.392
243.409
259.970
293.359
244.803
195.554
233.259
493.508
0
1
1
2
1
1
2
3
3
4
1
1
1
5
−0.59
−0.60
−0.58
−0.39
−0.29
−0.29
−0.13
−0.01
−0.04
0.03
−0.30 −1.40 −0.42 −0.68 −0.11
−0.41 −1.35 −0.32 −0.60 −0.14
−0.29 −1.15 −0.14 −0.35 −0.08
−0.42 −0.31 −0.20 −0.56 −0.17
−0.49 −0.30 −0.17 −0.56 −0.21
−0.37 −0.20 0.03 −0.37 −0.11
−0.34 −0.18 −0.01 −0.25 −0.08
−0.41 −0.21 −0.01 −0.27 −0.14
−0.32 −0.19 0.08 −0.17 −0.07
−0.39 −1.31 −0.27 −0.66 −0.20
−0.50
−0.26
−0.12
0.18
−0.20 −0.85 −0.27 −0.49
−0.35 −0.54 −0.05 −0.45
−0.48 −0.38 −0.33 0.12
0.04
0.09
0.30
d Etop. 0.698 160.861
a
GPCRL: GPCR ligand; ICM: Ion channel modulator; KI: Kinase inhibitor; NRL: Nuclear receptor ligand;
PI: Protease inhibitor; EI: Enzyme inhibitor; b TPSA: Total polar surface area; c NONI: number OH-NH interaction;
d Etop: Etoposide.

Molecules 2013, 18
1888
A parameter to determine good absorption of compounds is the value of cLogP. On this basis, for a
reasonable probability of good absorption, LogP value must not be greater than 5.0. Notably, the
cLogP values of phtalides 10–22 are greater than the etoposide value, suggesting that the hydrophobicity
of isobenzofuranone derivatives is greater than that of the compound used as positive control in the
biological assays. Normally, the drugs interacting with enzyme inside the human body have LogP
values between 2 and 5 [26]. In this respect, most of the studied compounds present values within this
range (Tables 4 and 5).
Toxicity risk alerts are an indication that the structure of a compound may be harmful. Analysis of
theoretical toxicity risks for these series using Osiris software revealed that all the compounds examined
were non-mutagenic, non-tumorigenic, non-irritating and without effects on mammalian reproduction
(Table 4). In addition, these compounds were evaluated as potential drugs through the drug-likeness
calculations, showing negative values (between −8.59 and −3.58, Table 4), indicating that compounds
10–22 do not contain fragments that are frequently present in commercial drugs [23,24].
Aqueous solubility of a compound significantly affects its absorption and distribution characteristics.
In general, it is desirable to obtain compounds which are soluble in a biological environment. A parameter
to evaluate the solubility is LogS. More than 80% of the drugs in the market have estimated LogS
values greater than −4 [19]. In the case of compounds 19 and 22, LogS values (−4.41 and −4.04,
respectively) are lower, compared to others in the series (Table 4).
Drug score values can be used to judge the compound’s overall potential to qualify it for a drug.
The values are the combination of drug likeness, toxicity risk, and some physicochemical parameters,
such as cLogP, solubility, and molecular weight [23,24]. These values would be used to evaluate the
potential of a candidate drug. As can be seen in Table 4, drug score values of compounds 10–22 are
comparable or higher in relation to the commercial drug etoposide.
Hydrogen-bonding capacity (the number of HBA) was estimated by considering the number of
nitrogen and oxygen atoms in the chemical structure. The number of HBD atoms was the sum of
hydrogen atoms bound to oxygen and to nitrogen atoms [23]. The values of these parameters for
compounds 10–22 are within the limit set by the Lipinski rules. This rule also suggests that two or
more violations in a compound show probability of bio-availability problems [27]. All the compounds
in Table 4 present zero violations of the rules, unlike epotoside, that has two rule violations.
In addition to LogP, total polar surface area (TPSA) is an important descriptor for prediction of drug
transport properties, including intestinal absorption, Caco-2 monolayer permeability, and blood-brain
barrier penetration [28,29]. This parameter was calculated using Molinspiration software based on the
sum of the surface belonging to polar atoms (usually oxygens, nitrogens, and attached hydrogens) [25].
Compounds with TPSA ≥ 140 A2 are thought to have poor oral bioavailability and TPSA ≤ 61 A2 are
thought to have good bioavailability [28]. Considering the TPSA values, compounds 10–22 (Table 5)
are expected to exhibit good bioavailability, based on the acceptable range. However, it must be
mentioned that TPSA ≤ 140 A2 is a necessary but not sufficient criterion for good bioavailability.
The number of rotatable bonds is a simple topological parameter of molecular flexibility. It has
been shown to be a very good descriptor of oral bioavailability of drugs [17]. Compounds 17, 18 and
19 exhibit greater flexibility among the compounds tested with nRotB = 3, 3, and 4, respectively, while
the commercial drug etoposide presented a value equal to 5 (Table 5).

Molecules 2013, 18
1889
Bioactivity of all the 13 compounds and etoposide were analyzed under different regular human
body receptors, with six criteria of known successful drug activity being observed in the areas of
GPCR ligand activity, ion channel modulation, kinase inhibition activity, nuclear receptor ligand
activity, protease inhibition activity, and enzyme inhibition activity. The higher the value of the score,
the better the probability of a molecule being active. Results of these parameters are presented (Table 5)
by numerical assignments. Like etoposide, all the compounds studied have consistent negative numerical
values for ion channel modulator and kinase inhibitor. In the other categories, the values for some
isobenzofuranones were positive.
Although no plane correlation could be found between the physical chemical properties of
isobenzofuranone derivatives and antiproliferative activity, some generalizations can be made. For
instance, the presence of the acetyl group on the benzene ring of compounds 14–19 seems to increase
biological activity. There is an apparent correlation between the values of cLogP with the antiproliferative
activity of these compounds, since the most active compounds have cLogP values in the range of 3.1–4.19.
The other compounds show lower lipophilicity values.
3. Experimental
3.1. General
Analytical grade phthalaldehydic acid, 8-diazabicyclo [5.4.0]undec-7-ene (DBU), cycloexane-1,3-dione,
5-methylcyclohexane-1,3-dione, 5,5-dimethyl cicloexane-1,3-dione (dimedone), 5-isopropylcyclohexane-
1,3-dione and dymethylaminopyridine (DMAP) were purchased from Aldrich (St. Louis, MO, USA).
Mercury (II) acetate, sodium acetate, acetic acid, acetonitrile and chloroform were purchased from
Vetec (Rio de Janeiro, Brazil). 1H and 13C-NMR spectra were recorded on a Bruker AVANCE DRX 400
spectrometer at 400 and 100 MHz, respectively, using MeOH-d4, CDCl3 and DMSO-d6 as solvents.
Infrared spectra were recorded on a Varian 660-IR, equipped with GladiATR scanning from 4000 to
500 cm−1. HRMS data were recorded under ESI conditions on a micrOTOF-QII Brucker spectrometer.
Melting points are uncorrected and were obtained with a MQAPF-301 melting point apparatus
(Microquimica, Campinas, Brazil). Analytical thin layer chromatography was carried out on TLC plates
recovered with 60GF254 silica gel. Column chromatography was performed over silica gel (60–230 mesh).
3.2. Synthesis of Compounds 11–13, Exemplified by the Synthesis of
3-(2-Hydroxy-6-oxocyclohex-1-enyl)isobenzofuran-1(3H)-one (11)
Cyclohexane-1,3-dione (0.891 g, 7.95 mmol), acetonitrile (10 mL) and DBU (1.06 mL, 7.1 mmol)
were added to a round-bottomed flask (50 mL). The mixture was magnetically stirred at room
temperature for 5 min. Phthaldehydic acid (10, 1.070 g; 7.1 mmol) was added and the mixture was
refluxed for 7 h. The reaction was quenched by the addition of aqueous 10% HCl (10 mL), followed
by ethyl acetate (100 mL). The layers were separated and the organic layer was washed with water
(2 × 20 mL) and brine (10 mL), dried over anhydrous sodium sulphate and concentrated under reduced
pressure. The resulting material was recrystallized from ethyl acetate. Compound 11 was obtained as a
white solid in 64% yield (1.121 g; 4.6 mmol). The structure of the compound is supported by the


following data: TLC R = 0.20 (ethyl acetate). mp 217.5–218.0 °C. IR (ATR, cm−1)
: 2960, 2917,
max
f

Molecules 2013, 18
1890
2887, 2555 (broad band), 1758, 1565, 1380, 1281, 1056, 1025, 944. 1H-NMR (400 MHz, DMSO-d6): 
1.83–1.91 (m, 2H, H-4'), 2.26–2.45 (m, 4H, H-3'/H-5'), 6.59 (s, 1H, H-3), 7.30 (d, 1H, J = 7.6 Hz,
H-4), 7.50 (dd, 1H, J = 7.6, 7.2 Hz, H-5), 7.65 (dd, 1H, J = 7.6, 7.2 Hz, H-6), 7.78 (d, 1H, J = 7.6 Hz,
H-7). 13C-NMR (100 MHz, DMSO-d6):  20.1 (C-3'/C-5'), 32.6 (C-4'), 74.3 (C-3), 109.1 (C-1'), 121.4
(C-4), 124.2 (C-7), 126.5 (C-8), 128.0 (C-6), 133.6 (C-5), 150.7 (C-9), 170.7 (C-1), 188.0 (C-2').
HREIMS m/z (M+H+): Calculated for C14H13O4, 245.0814; found: 245.0840.
Compounds 12 and 13 were prepared using a procedure similar to that described for compound 11.
3-(2-Hydroxy-4-methyl-6-oxocyclohex-1-enyl)isobenzofuran-1(3H)-one (12): The compound was
obtained as a white solid in 68% yield. The structure of the compound is supported by the following


data: TLC Rf = 0.50 (ethyl acetate). mp. 214.6–218.3 °C. IR (ATR, cm−1)
: 2960, 2917, 2886,
max
1
2565 (broad band), 1757, 1564, 1380, 1281, 1060, 944, 787, 740, 690, 538. H-NMR (400 MHz,
MeOH-d4):  1.08 (d, 3H, J = 4.8, -CH3), 2.13–2.55 (m, 5H, H-4', H-3'/H-5'), 6.69 (s, 2H, H-3), 7.31
(d, 1H, J = 7.6 Hz, H-4), 7.49 (dd, 1H, J = 7.6, 7.2 Hz, H-5), 7.64 (dd, 1H, J = 7.6, 7.2 Hz, H-6), 7.81
(d, 1H, J = 7.6 Hz, H-7); 13C-NMR (100 MHz, MeOH-d4):  21.0 (-CH3), 29.5 (C-3'/C-5'), 42.2 (C-4'),
76.6 (C-3), 110.8 ( C-1'), 122.7 (C-4), 125.7 (C-7), 128.2 (C-8), 129.5 (C-6), 135.2 (C-5), 152.4 (C-9),
174.2 (C-1), 189.7 (C-2'). HREIMS m/z (M+H+): Calculated for C15H15O4, 259.0970; found: 259.0998.
3-(2-Hydroxy-4-isopropyl-6-oxocyclohex-1-enyl)isobenzofuran-1(3H)-one (13): The compound was
obtained as a white solid in 69% yield. The structure of the compound is supported by the following


data: TLC R = 0.08 (hexane-ethyl acetate 1:3 v/v). mp 176.7–177.8 °C. IR (ATR, cm−1)
: 2964,
max
f
1
2872, 2534 (broad band), 2034, 1758, 1555, 1466, 1370, 1341, 1252, 1090, 1063, 950, 727. H-NMR
(300 MHz, MeOH-d4):  0.94 (d, 6H, J = 6.9 Hz, -CH(CH3)2), 1.57–1.67 (m, 1H, -CH(CH3)2), 1.83–1.96
(m, 1H, H-4'), 2.22–2.51 (m, 4H, H-3' and H-5'), 6.68 (s, 1H, H-3), 7.31 (dd, 1H, J = 7.5, 0.9, H-4),
7,50 (t, 1H, J = 7.5, H-5), 7.64 (td, 1H, J = 7.5, 1.2, H-6), 7.80 (d, 1H, J = 7.5, H-7). 13C-NMR (75 MHz,
MeOH-d4):  18.7 (-CH(CH3)2), 31.7 (-CH(CH3)2), 36.8 (C-3'/C-5'), 39.5 (C-4'), 75.3 (C-3), 109.4
(C-1'), 121.4 (C-4), 124.4 (C-7), 126.8 (C-8), 128.2 (C-6), 139.9 (C-5), 151.0 (C-9), 172.9 (C-1), 189,4
(C-2'). HREIMS m/z (M+H+): Calculated for C17H19O4, 287.1283; found: 287.1260.
3.3. Synthesis of Compounds 14–16, Exemplified by the Synthesis of
3-(2,6-Dihydroxyphenyl)-isobenzofuran-1(3H) one (14)
A 50 mL round-bottomed flask was charged with compound 11 (477 mg, 1.95 mmol), acetic acid
(20 mL), Hg(OAc)2 (1,897 mg; 5.93 mmol) and NaOAc (481 mg, 5.86 mmol). The resulting mixture
was stirred under reflux for 5 h. The reaction mixture was cooled and 5 mL of HCl 1 mol L−1 was
added and stirred for an additional 15 min. The mixture was filtered through a Celite pad and the
filtrate diluted with ethyl acetate (60 mL). The organic layer was separated, washed with saturated
sodium bicarbonate aqueous solution (2 × 10 mL), water (5 mL), brine (5 mL) and 0.200 mol L−1
sodium EDTA aqueous solution (2 × 15 mL). The organic layer was dried over sodium sulphate, filtered,
concentrated under reduced pressure and the residue purified by silica gel column chromatography
(hexane-ethyl acetate; 1:3 v/v). Compound 11 was obtained as a white solid in 68% yield (320 mg;
1.32 mmol). The structure of the compound is supported by the following data: TLC Rf = 0.70

Molecules 2013, 18
1891

(hexane-ethyl acetate 1:3 v/v). mp 238.6–239.8 °C. IR (ATR, cm−1)
: 3470 (broad band), 3296

max
(broad band), 1712, 1614, 1469, 1011, 945, 715, 587. 1H-NMR (400 MHz, CDCl3 + DMSO-d6):  6.29
(d, 2H, J = 8.0 Hz, H-3'/H-5'), 6.92 (t, 1H, J = 8.0 Hz, H-4), 7.02 (s, 1H, H-3), 7.31 (d, 1H, J = 7.2 Hz,
H-4), 7.47 (t, 1H, J = 7.6 Hz, H-6), 7.59 (t, 1H, J = 7.2 Hz, H-5), 7.81 (d, 1H, J = 7.6 Hz, H-7). 13C-NMR
(100 MHz, CDCl3 + DMSO-d6):  75.6 (C-3), 106.9 (C-3'/C-5'), 108.6 (C-1'), 121.8 (C-4), 124.2 (C-7),
127.2 (C-8), 127.9 (C-6), 130.2 (C-4'), 133.3 (C-5), 151.1 (C-9), 157.5 (C-2'/C-6'), 171.5 (C-1). HREIMS
m/z (M+H+): Calculated for C14H11O4, 243.0657; found: 243.0658.
Compounds 15 and 16 were prepared using a procedure similar to that described for compound 14.
3-(2,6-Dihydroxy-4-methylphenyl)-isobenzofuran-1(3H)-one (15): The compound was obtained as a
pale yellow solid via aromatization of compound 12 in 71% yield (purified by silica gel column
chromatography, using hexane-ethyl acetate 1:3 v/v as the eluting solvent). The structure of the compound
is supported by the following data: TLC Rf = 0.82 (hexane-ethyl acetate 1:3 v/v). mp 228–231 °C. IR

(ATR, cm−1)
: 3579, 3201 (broad band), 2924, 2853, 1721, 1618, 1595, 1305, 1046, 952, 821,

max
734, 684, 535. 1H RMN (200 MHz, CDCl3 + MeOH-d4):  1.94 (s, 3H, -CH3), 5.94 (s, 2H, H-3'/H-5'),
6.82 (s, 1H, H-3), 7.11 (d, 1H, J = 7.2 Hz, H-4); 7.16–7.44 (m, 2H, H-5 e H-6), 7.62 (d, 1H, J = 7.2 Hz,
H-7). 13C-NMR (50 MHz, CDCl3 + MeOH-d4):  22.5 (-CH3), 72.2 (C-3), 106.9 (C-1'), 109.1 (C-3'/C-5'),
123.2 (C-4), 125.4 (C-6), 128.5 (C-8), 128.9 (C-7), 134.4 (C-5), 141.9 (C-4'), 152.6 (C-9), 158.3
(C-2'/C-6'), 173.2 (C-1). HREIMS m/z (M+H+): Calculated for C15H13O4, 257.0814; found: 257.0880.
3-(2,6-Dihydroxy-4-isopropylphenyl)-isobenzofuran-1(3H)-one (16): The compound was obtained as a
viscous orange oil via aromatization of compound 13 in 94% yield (purified by silica gel column
chromatography, using hexane-ethyl acetate 1:1 v/v as the eluting solvent). The structure of the
compound is supported by the following data: TLC Rf = 0.44 (hexane-ethyl acetate 1:1 v/v). IR (ATR,


cm−1)
: 3305 (broad band), 2959, 2924, 2870, 2159, 1726, 1621, 1596, 1433, 1034, 732. 1H-NMR
max
(300 MHz, MeOH-d4):  1,17 (d, 6H, J = 6.9 Hz, -CH(CH3)2), 2.68 (hept, 1H, J = 6.9 Hz;
-CH(CH3)2), 6.17 (s, 2H; H-3'/H-5'), 7.02 (s, 1H, H-3); 7.30 (dd, 1H, J = 7.5, J = 0.9 Hz, H-4),
7.49 (t, 1H, J = 7.2 Hz, H-5), 7.63 (td, 1H, J = 7.5, 1.2 Hz, H-6), 7.82 (d, 1H, J = 7.5 Hz, H-7). 13C-NMR
(75 MHz, MeOH-d4) : 22.9 (-CH(CH3)2), 34.2 (-CH(CH3)2), 76.8 (C-3), 104.6 (C-3/C-5'), 105.8 (C-1'), 121.8
(C-4), 124.1 (C-6), 127.0 (C-8), 128.0 (C-7), 133.7 (C-5), 151.8 (C-9), 152.3 (C-4'), 157.6 (C-2'/C-6'),
173.4 (C-1). HREIMS m/z (M+H+): Calculated for C17H17O4, 285.1127; found: 285.1116.
3.4. Synthesis of Compounds 17–19, Exemplified by the Synthesis of
2-(3-Oxo-1,3-dihydroisobenzofuran-1-yl)-1,3-phenylene diacetate (17)
A round-bottomed flask (25 mL) was charged with compound 14 (0.109 g, 0.45 mmol), chloroform
(5 mL), acetic anhydride (0.16 mL, 1.62 mmol), and a catalytic amount of DMAP (0.005 g, 0.045 mmol).
The reaction mixture was stirred at room temperature for 12 h. The solvent was removed and
compound 17 was purified by recrystallization from ethyl acetate affording a white solid in 44% yield
(0.064 g, 0.20 mmol). The structure of the compound is supported by the following data: TLC Rf = 0.54

(hexane-ethyl acetate 1:1 v/v). mp. 175.9–177.8 °C. IR (ATR, cm−1)
: 1756, 1611, 1465, 1369,

max
1
1285, 1170, 1023, 975; H-NMR (200 MHz, DMSO-d6):  2.01 (brs, 6H, 2 × -COCH3), 6.85 (s, 1H,

Molecules 2013, 18
1892
H-3), 7.08 (d, 2H, J = 8.2 Hz, H-3'/H-5'), 7.25 (d, 1H, J = 6.8 Hz, H-4), 7.53 (t, 1H, J = 8.2 Hz, H-4'),
13
7.58–7.75 (m, 2H, H-5 and H-6), 7.95 (d, 1H, J = 7.4 Hz, H-7). C-NMR (50 MHz, DMSO):  22.0
(-COCH3), 76.0 (C-3), 122.3 (C-3'/C-5'), 123.2 (C-1'), 124.4 (C-4), 126.6 (C-7), 127.3 (C-8), 131.2
(C-6), 132.5 (C-4'), 136.5 (C-5), 150.67 (C-9), 151.61 (C-2'/C-6'), 170.5 (C-1), 172.0 (-COCH3).
HREIMS m/z (M+H+): Calculated for C18H15O6, 327.0869; found: 327.0848.
Compounds 18 and 19 were prepared using a procedure similar to that described for compound 17.
5-Methyl-2-(3-oxo-1,3-dihydroisobenzofuran-1-yl)-1,3-phenylene diacetate (18): The compound was
obtained as a pale yellow solid from compound 15 in 93% yield (after purification by silica gel column
chromatography, using hexane-ethyl acetate 1:2 v/v as the eluting solvent). The structure of the compound
is supported by the following data: TLC Rf = 0.8 (hexane-ethyl acetate 1:2 v/v) mp. 171.5–172.3 °C.

1
IR (ATR, cm−1)
: 2925, 2855, 1758, 1621, 1172, 1040, 974, 692, 738. H-NMR (200 MHz,

max
DMSO-d6):  1.99 (brs, 6H, 2 × -COCH3), 2.31 (s, 3H, CH3), 6.78 (s, 1H, H-3), 6.94 (s, 2H, H-3'/H-
5'), 7.23 (d, 1H, J = 7.4 Hz, H-4), 7.61 (dd, 1H, J = 7.4, 7.2 Hz, H-5), 7.73 (dd, 1H, J = 7.4, 7.2 Hz,
H-6), 7.93 (d, 1H, J = 7.2 Hz, H-7). 13C-NMR (50 MHz, DMSO-d6):  22.0 (-COCH3), 22.3 (-CH3), 76.0
(C-3), 119.3 (C-3'/C-5'), 123.6 (C-1'), 124.4 (C-4), 126.5 (C-6), 127.3 (C-8), 131.0 (C-7), 136.4 (C-5),
142.9 (C-9'), 150.8 (C-4'), 151.4 (C-2'/C-6'), 170.5 (C-1), 171.9 (-COCH3). HREIMS m/z (M+H+):
Calculated for C19H17O6, 341.1025; found: 341.1030.
5-Isopropyl-2-(3-oxo-1,3-dihydroisobenzofuran-1-yl)-1,3-phenylene diacetate (19): This compound
was obtained as a solid in 78% yield (after purification by recrystallization from ethyl acetate) from
compound 15. The structure of the compound is supported by the following data: TLC Rf = 0.81


(hexane-ethyl acetate 1:1 v/v). mp. 157.5–158.1 °C. IR (ATR, cm−1)
: 2963, 2930, 2870, 1756,
max
1620, 1366, 1288, 1179, 1030, 973, 739, 562. 1H-NMR (200 MHz, DMSO-d6):  1.16 (d, 1H, J = 7.0 Hz,
-CH(CH3)2), 1.98 (brs, 6H, 2 × -COCH3), 2.89 (hept, 1H, J = 7.0 Hz, -CH(CH3)2, 6.78 (S, 1H, H-3),
7.00 (s, 2H, H-3'/H-5'), 7.26 (d, 1H, J = 7.2 Hz, H-4), 7.54–7.78 (m, 2H, H-5 and H-6), 7.93 (d, 1H,
J = 7.2 Hz, H-7). 13C-NMR (50 MHz, DMSO-d6):  22.0 (-COCH3), 25.0 (-CH(CH3)2), 34.80
(-CH(CH3)2), 76.0 (C-3), 119.6 (C-3'/C-5'), 121.0 (C-1'), 124.5 (C-4), 126.5 (C-6), 127.3 (C-8), 131.1
(C-7), 136.4 (C-5), 150.7 (C-9), 151.5 (C-2'/C-6'), 153.9 (C-4') 170.5 (C-1), 171.9 (-COCH3).
HREIMS m/z (M+H+): Calculated for C21H21O6, 369.1338; found: 369.1418.
3.5. Synthesis of 3-(2-Hydroxy-4,4-dimethyl-6-oxo-cyclohexen-1-yl)isobenzofuran-1(3H)-one (20)
Dimedone (500 mg; 3.57 mmol), chloroform (5 mL), and DBU (0.53 mL; 3.57 mmol) were placed
into a 25 mL round-bottomed flask. The resulting mixture was stirred at room temperature for 5 min
followed by the addition of 5-hydroxyisobenzofuran-1(3H)-one (19) (495 mg; 3.30 mmol). The
reaction mixture was stirred at room temperature for 5 h, quenched with 10% HCl (5 mL), and diluted
with ethyl acetate (100 mL). The organic layer was separated, washed with water (2 × 20 mL) and
brine (10 mL), dried over sodium sulphate, filtered and concentrated under reduced pressure.
Compound 18 was obtained as a white solid in 95% yield (850 mg; 3.12 mmol) after recrystallization
from ethyl acetate. The structure of the compound is supported by the following data: TLC Rf = 0.10


(hexano-ethyl acetate 1:1 v/v). mp 212.1–213.0 °C. IR (ATR, cm−1):
2962, 2934, 2884, 2535
max

Molecules 2013, 18
1893
1
(broad band), 1763, 1569, 1382, 1321, 1121, 1059, 942, 738, 694, 613, 574. H-NMR (400 MHz,
MeOH-d4):  1.09 (s, 6H, 2 × CH3), 2.35 (s, 4H, H-3'/H-5'), 6.70 (s, 1H, H-3), 7.31 (d, 1H, J = 7.6 Hz,
H-4), 7.50 (t, 1H, J = 7.6 Hz, H-5), 7.66 (t, 1H, J = 7.6 Hz, H-6), 7.81 (d, 1H, J = 7.6 Hz, H-7);
13C-NMR (100 MHz, MeOH-d4):  28.5 (-CH3), 33.1 (C-4'), 47.9 (C-3'/C-5'), 76.6 (C-3), 110.1 (C-1'),
122.6 (C-4), 125.8 (C-7), 128.2 (C-8), 129.5 (C-6), 135.2 (C-5), 152.4 (C-9), 174.2 (C-1), 188.9 (C-2').
HREIMS m/z (M+H+): Calculated for C16H17O4, 273.1127; found: 273.1124.
3.6. Synthesis of Compounds 21 and 22, Exemplified by the Synthesis
3-(2-Hydroxy-5-oxocyclopent-1-enyl)isobenzofuran-1(3H)-one (21)
Cyclopentane-1,3-dione (0.357 g; 3.64 mmol), chloroform (5 mL), and DBU (0.56 mL, 3.70 mmol)
were added to a 25 mL round-bottomed flask. The mixture was stirred at room temperature for 5 min.
Phthalaldehydic acid (10) (0.533 g, 3.55 mmol) was added and the resulting mixture was refluxed for
5 h, quenched with 10% HCl (5 mL), and diluted with ethyl acetate (100 mL). The organic layer was
separated, washed with water (2 × 20 mL) and brine (10mL), dried over sodium sulphate, filtered and
concentrated under reduced pressure. Compound 21 was obtained as a white solid in 53% yield (0.448 g,
1.94 mmol) after recrystallization from ethyl acetate. The structure of the compound is supported by
the following data: TLC Rf = 0.10 (hexane-ethyl acetate 1:1 v/v). mp. 203.6–205.2 °C. IR (ATR,

cm−1):
2987, 2930, 2370 (broad band), 2366, 2339, 1763, 1648, 1557, 1368, 1281, 1048, 963.

max
1H-NMR (200 MHz, CDCl3 + DMSO-d6)  2.27 (brs, 4H, 2 × -CH2), 6.07 (s, 1H, H-3), 7.11 (d, 1H,
J = 7.2 Hz, H-4), 7.23–7.45 (m, 2H, H-5 and H-6), 7.62 (d, 1H, J = 7.2 Hz, H-7). 13C-NMR (50 MHz,
CDCl3 + DMSO-d6):  31.8 (-CH2), 74.5 (C-3), 112.6 (C-1'), 123.3 (C-4), 126.0 (C-7), 127.5 (C-8),
129.7 (C-6), 134.9 (C-5), 150.1 (C-9), 172.2 (C-1), 197.3 (C-2'). HREIMS m/z (M+H+): Calculated for
C13H11O4, 231.0657; found: 231.0672.
Compound 22 was obtained as a brown solid in 69% yield, using a procedure similar to that described
for compound 21. The structure of this compound is supported by the following data: TLC Rf = 0.10


(hexane-ethyl acetate 1:1 v/v). mp. 214.0–215.3 °C. IR (ATR, cm−1): max 3068, 2922, 1770, 1741,
1702, 1266, 1221, 1054. 1H-NMR (400 MHz, CDCl3 + DMSO-d6)  4.12 (d, 1H, J = 2.4 Hz, H-1'),
6.20 (d, 1H, J = 2.4 Hz, H-3), 7.84 (m, 8H, H-4, H-5, H-6, H-7, H-3', H-4', H-5', and H-6').
13C-NMR. 55,0 (C-1'), 77.3 (C-3), 124,2 (C-4), 123.1 (C-3'), 123.6 (C-6'), 125.3 (C-7), 125.8 (C-6), 129.5
(C-8), 134.4 (C-4'/C-5'), 136.1 (C-5), 142.1 (C-8'), 142.5 (C-9'), 147.4 (C-9), 169.4 (C-1), 194.9 (C-2’), 196.3
(C-7'). HREIMS m/z (M+H+): Calculated for C17H11O4, 279.0657; found: 279.0665.
3.7. Antiproliferative Activity Assays
The human cell lines U937 (lymphoma) and K562 (myeloid leukemia) were purchased from ATCC
(Rockville, MD, USA). They were cultured in a RPMI 1640 medium (Sigma Aldrich, St. Louis, MO,
USA) supplemented with 10% fetal bovine serum (LGC, Campinas, Brazil), 100 μg/mL streptomycin
and 100 U/mL penicillin at 37 °C under 5.0% CO2 atmosphere. To evaluate the antiproliferative
activity of compounds 10–22, U937 and K562 cells were grown in 96-well plates (TPP, Trasadingen,
Switzerland) at a density of 2.0 × 104 cells per well at different compound concentrations (0–100 µM)
and etoposide (VP-16) (0–100 µM). No precipitation was observed for any of the compounds at the

Molecules 2013, 18
1894
assayed concentrations. Cell viability was determined by the modified colorimetric 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich) assay. After 24 and/or 48 h, MTT
(0.5 mg/mL) was added to the wells (2 h, 37 °C), followed by the removal of MTT solution and
addition of 100 µL/well of dimethyl suphoxide (DMSO, Sigma Aldrich) to solubilize the formazan
crystals. Absorbances were measured at 540 nm. Each analysis was performed in quadruplicate and the
results were normalized considering the cultures treated with the vehicle alone (1% DMSO). The data
were analyzed as the mean ± SD and IC50 was determined using GraphPad Prism 5.0 software.
4. Conclusions
We have demonstrated that several isobenzofuranone possessing alicyclic and aromatic groups
attached to C-3 position exhibit significant antiproliferative active against two cancer cell lines. In
some cases, the biological effect was higher than that displayed by the commercial drug etoposide
(VP-16). The in silico favorable drug-like parameters predicted and shown above suggest that the
isobenzofuranones prepared in this work possess good physicochemical properties that qualify them as
promising candidates for future studies. Further investigations to validate their potential as anti-tumor
compounds, including evaluation of their toxicity against human PMBC cells and in vivo assays using
murine animal models, are under way and will be published elsewhere.
Acknowledgments
The authors are grateful to the Brazilian agencies: Conselho Nacional de Desenvolvimento
Científico e Tecnológico (CNPq) for research grant (to G.C.B); Coordenação de Aperfeiçoamento de
Pessoal de Nível Superior (CAPES) research fellowhships (to W.L.P.); Fundação de Amparo a Pesquisa
de Minas Gerais (FAPEMIG) for research grant (to R.R.T) and research fellowship (to F.M.O.).
References
1. Huang, X.-Z.; Zhu, Y.; Guan, X.-L.; Tian, K.; Guo, J.-M.; Wang, H.-B.; Fu, G.-M. A novel
antioxidant isobenzofuranone derivative from fungus Cephalosporium sp. AL031. Molecules
2012, 17, 4219–4224.
2. Strobel, G.; Ford, E.; Worapong, J.; Harper, J.K.; Arif, A.M.; Grant, D.M.; Fung, P.C.W.;
Chau, R.M.W. Isopestacin, an isobenzofuranone from Pestalotiopsis microspora possessing
antifungal and antioxidant activities. Phytochemistry 2002, 60, 170–183.
3. Ma, F.; Gao, Y.; Qiao, H.; Hu, X.; Chang, J. Antiplatelet activity of 3-butyl-6-bromo-1(3H)-
isobenzofuranone on rat platelet aggregation. J. Thromb. Thrombolysis 2012, 33, 64–73.
4. Cardozo, J.A.; Braz-Filho, R.; Rincón-Velandia, J.; Guerrero-Pabón, M.F. 3-butil-isobenzofuranona:
Un compuesto aislado de Apium graveolens com actividad anticonvulsivante. Rev. Colomb. Cienc.
Quim. Farm. 2005, 34, 69–76.
5. Arnone, A.; Assante, G.; Nasini, G.; Strada, S.; Vercesi, A. Cryphonectric acid and other minor
metabolites from a hypovirulent strain of Cryphonectria parasítica. J. Nat. Prod. 2002, 65, 48–50.
6. Demuner, A.J.; Barbosa, L.C.A.; Veiga, T.A.M.; Barreto, R.W.; King-Diaz, B.; Lotina-Hennsen, B.
Phytotoxic constituents from Nimbya alternantherae. Biochem. Syst. Ecol. 2006, 34, 790–795.

Molecules 2013, 18
1895
7. Logrado, L.P.L.; Santos, C.O.; Romeiro, L.A.S.; Costa, A.M.; Ferreira, J.R.O.; Cavalcanti, B.C.;
de Moraes, O.M.; Costa-Lotufo, L.V.; Pessoa, C. Synthesis and cytotoxicity screening of substituted
isobenzofuranones designed from anarcadic acids. Eur. J. Med. Chem. 2010, 45, 3480–3489.
8. Teixeira, R.R.; Barbosa, L.C.A.; Maltha, C.R.A.; Rocha, M.E.; Bezerra, D.P.; Costa-Lotufo, L.V.;
Pessoa, C.; Moraes, M.O. Synthesis and cytotoxic activity of some 3-benzyl-5-arylidenefuran-
2(5H)-ones. Molecules 2007, 12, 1101–1116.
9. Barbosa, L.C.A.; Pereira, U.A.; Maltha, C.R.A.; Teixeira, R.R.; Valente, V.M.M.; Ferreira, J.R.O.;
Costa-Lotufo, V.; Moraes, M.O.; Pessoa, C. Synthesis and Biological Evaluation of 2,5-bis(alkylamino)-
1,4-benzoquinones. Molecules 2010, 15, 5629–5643.
10. Barbosa, L.C.A.; Nogueira, L.B.; Maltha, C.R.A.; Teixeira, R.R.; Silva, A.A. Synthesis and
phytogrowth properties of oxabicyclic analogues related to helminsthosporin. Molecules 2009, 14,
160–173.
11. Teixeira, R.R.; Barbosa, L.C.A.; Forlani, G.; Piló-Veloso, D.; de Mesquita Carneiro, J.W.
Synthesis of photosynthesis-inhibiting nostoclide analogues. J. Agric. Food Chem. 2008, 56,
2321–2329.
12. Pahari, P.; Senapati, B.; Mal, D. Regiospecific synthesis of isopestacin, a naturally occurring
isobenzofuranone antioxidante. Tetrahedron Lett. 2004, 45, 5109–5112.
13. Mal, D.; Pahari, P.; De, S.R. Regiospecific synthesis of 3-(2,6-dihydroxyphenyl)phtalides:
Application to the synthesis of isopestacin and cryphonectric acid. Tetrahedron 2007, 63,
11781–11792.
14. Oliver, J.E.; Wilzer, K.R.; Waters, R.M. Synthesis of 1-(2,6-Dihydroxyphenyl)-1-alkanones and
Benzophenone by Aromatization of 2-Acyl-3-hydroxy-2-cyclohexene-1-ones with Mercuric
Acetate. Synthesis 1990, 1990, 1117–1119.
15. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational
approaches to estimate solubility and permeability in drug discovery and development settings.
Adv. Drug Deliv. Rev. 1997, 23, 3–25.
16. Veber, D.F.; Johnson, S.R.; Cheng, H.-Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular
properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45,
2615–2623.
17. Tetko, I.V. Computing chemistry on the web. Drug Discov. Today 2005, 10, 1497–1500.
18. Molinspiration Cheminformatics. Available online: http://www.molinspiration.com/ (accessed on
September 2012).
19. Alafeefy, A.M.; Alqasoumi, S.I.; Ashour, A.E.; Masand, V.; Al-Jaber, N.A.; Hadda, T.B.;
Mohameda, M.A. Quinazoline-etyrphostin as a new class of antitumor agents, molecular properties
prediction, synthesis and biological testing. Eur. J. Med. Chem. 2012, 53, 133–140.
20. Ali, P.; Meshram, J.; Sheikh, J.; Tiwari, V.; Dongre, R.; Hadda, T.B. Predictions and correlations
of structure activity relationship of some aminoantipyrine derivatives on the basis of theoretical
and experimental ground. Med. Chem. Res. 2012, 21, 157–164.
21. Mahajan, D.T.; Masand, V.H.; Patil, K.N.; Hadda, T.B.; Jawarkar, R.D.; Thakur, S.D.; Rastija, V.
CoMSIA and POM analyses of anti-malarial activity of synthetic prodiginines. Bioorg. Med.
Chem. Lett. 2012, 22, 4827–4835.

Molecules 2013, 18
1896
22. Chohan, Z.H.; Sumrra, S.H.; Youssoufi, M.H.; Hadda, T.B. Metal based biologically active
compounds: Design, synthesis, and antibacterial/antifungal/cytotoxic properties of triazole-derived
Schiff bases and their oxovanadium(IV) complexes. Eur. J. Med. Chem. 2010, 45, 2739–2747.
23. Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov.
Today Technol. 2004, 1, 337–341.
24. Proudfoot, R. Drugs, leads, and drug-likeness: An analysis of some recently launched drugs.
Bioorg. Med. Chem. Lett. 2012, 12, 1647–1650.
25. Jarrahpour, A.; Fathi, J.; Mimouni, M.; Hadda, T.B.; Sheikh, J.; Chohan, Z.; Parvez, A.
Petra, Osiris and molinspiration (POM) together as a successful support in drug design:
Antibacterial activity and biopharmaceutical characterization of some azo schiff bases.
Med. Chem. Res. 2012, 21, 1984–1990.
26. Tambunan, U.S.F.; Bramantya, N.; Parikesit, A.A. In silico modification of suberoylanilide
hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
BMC Bioinformatics 2011, 12, S13–S23.
27. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational
approaches to estimate solubility and permeability in drug discovery and development settings.
Adv. Drug Deliv. Rev. 2001, 46, 3–26.
28. Clark, D.E. Rapid calculation of polar molecular surface area and its application to the prediction
of transport phenomena. 1. Prediction of Intestinal Absorption. J. Pharm. Sci. 1999, 88, 807–814.
29. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of
Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties.
J. Med. Chem. 2000, 43, 3714–3717.
Sample Availability: Samples of the compounds 11–22 are available from the authors.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).